Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis

Annals of Internal Medicine

Volumn 138, Issue 3, 2003, Pages 176-186

  Inadomi, John M ^b   Sampliner, Richard ^b   Lagergren, Jesper ^b   Lieberman, David ^b   Fendrick, A Mark ^b   Vakil, Nimish ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; ARTICLE; BARRETT ESOPHAGUS; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DYSPLASIA; FINANCIAL MANAGEMENT; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST;

EID: 0037418145     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-3-200302040-00009     Document Type: Article

References (63)

1. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-95. [PMID: 12190150]
2. Streitz JM Jr, Ellis FH Jr, Tilden RL, Erickson RV. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol. 1998;93:911-5. [PMID: 9647017]
3. Eloubeidi MA, Homan RK, Martz MD, Theobald KE, Provenzale D. A cost analysis ofoutpatient care for patients with Barrett's esophagus in a managed care setting. Am J Gastroenterol. 1999;94:2033-6. [PMID: 10445524]
4. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL, et al. Cost effectiveness of detecting Barrett's cancer. Gut. 1996;39:574-9. [PMID: 8944568]
5. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol. 1988;83:291-4. [PMID: 3125739]
6. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043-53. [PMID: 10445526]
7. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:670-80. [PMID: 8172136]
8. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287:1972-81. [PMID: 11960540]
9. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607-19.
10. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333-8. [PMID: 10930368]
11. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-5. [PMID: 9040193]
12. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340:825-31. [PMID: 10080844]
13. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology. 1999; 116:277-85. [PMID: 9922307]
14. Caygill CP, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol. 1999;11:1355-8. [PMID: 10654794]
15. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458. [PMID: 6668990]
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38. [PMID: 8246705]
17. Bonelli L. Barrett's esophagus: results of a multicentric survey. G.O.S.P.E. (Gruppo Operativo per lo Studio delle Precancerosi Esofagee. Endoscopy. 1993; 25:652-4. [PMID: 8119225]
18. Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-24. [PMID: 3781178]
19. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH, et al. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol. 1996;91:981-6. [PMID: 8633592]
20. Caygill CP, Reed PI, Hill MJ, Watson A. An initial comparison of nine centres registering patients with the UK National Barrett's Oesophagus Registry (UKBOR). Eur J Cancer Prev. 1999;8:539-42. [PMID: 10643944]
21. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol. 1996;91:1507-11. [PMID: 8759651]
22. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249-56. [PMID: 2703113]
23. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol. 1999;94:2037-42. [PMID: 10445525]
24. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-6. [PMID: 9362182]
25. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol. 2000;95: 2086-93. [PMID: 10950062]
26. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 1999;94:3413-9. [PMID: 10606296]
27. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology. 1984;87:927-33. [PMID: 6468881]
28. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985;313:857-9. [PMID: 4033716]
29. Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med. 1991;151:2212-6. [PMID: 1953225]
30. Sharma P, Reker D, Falk G, Johnston M, Weston A, Sampliner R. Progression of Barrett's esophagus to high grade dysplasia and cancer: Preliminary results of the BEST (Barrett's Esophagus Study) trial [Abstract]. Gastroenterology. 2001;120:A16.
31. Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Barrett's oesophagus. J Gastroenterol Hepatol. 1991;6:1-22. [PMID: 1883971]
32. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol. 1998;93:536-41. [PMID: 9576444]
33. Schoenfeld P, Johnston M, Piorkowski M, Jones DM, Eloubeidi M, Provenzale D. Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's esophagus. Am J Gastroenterol. 1998;93:906-10. [PMID: 9647016]
34. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol. 2000; 95:1888-93. [PMID: 10950031]
35. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg. 1988;75:760-3. [PMID: 3167523]
36. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut. 1989;30:14-8. [PMID: 2920919]
37. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331-8. [PMID: 11343480]
38. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol. 1999;94:3420-6. [PMID: 10606297]
39. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg. 1993;105:383-7. [PMID: 8445916]
40. Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. Gut. 1992;33:1454-8. [PMID: 1452066]
41. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633-40. [PMID: 11874995]
42. Ellis FH Jr, Heatley GJ, Krasna MJ, Williamson WA, Balogh K. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg. 1997;113:836-46. [PMID: 9159617]
43. Skinner DB. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg. 1983;85:59-71. [PMID: 6848888]
44. Ellis FH Jr, Gibb SP, Watkins E Jr. Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia. Ann Surg. 1983; 198:531-40. [PMID: 6194763]
45. Nguyen NT, Schauer P, Luketich JD. Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. Surgery. 2000;127:284-90. [PMID: 10715983]
46. Wolfe WG, Vaughn AL, Seigler HF, Hathom JW, Leopold KA, Duhaylongsod FG. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg. 1993;105:749-55. [PMID: 8469009]
47. Galandiuk S, Hermann RE, Cosgrove DM, Gassman JJ. Cancer of the esophagus. The Cleveland Clinic experience. Ann Surg. 1986;203:101-8. [PMID: 3942414]
48. DeMeester TR, Zaninotto G, Johansson KE. Selective therapeutic approach to cancer of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1988;95: 42-54. [PMID: 2447446]
49. Wu YK, Huang KC. Chinese experience in the surgical treatment of carcinoma of the esophagus. Ann Surg. 1979;190:361-5. [PMID: 485610]
50. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381-90. [PMID: 6155968]
51. Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813-21. [PMID: 7967662]
52. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut. 1998;43: 216-22. [PMID: 10189847]
53. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg. 1992;54:199-204. [PMID: 1637206]
54. National Center for Health Statistics. Vital Statistics of the United States 2000. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Data Services; 2001.
55. Silvis SE, Nebel O, Rogers G, Sugawa C, Mandelstam P. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA. 1976;235:928-30. [PMID: 128642]
56. Habr-Gama A, Waye JD. Complications and hazards of gastrointestinal endoscopy. World J Surg. 1989;13:193-201. [PMID: 2658366]
57. Gorelick AB, Inadomi JM, Barnett JL. Unsedated small-caliber esophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. J Clin Gastroenterol. 2001;33:210-4. [PMID: 11500609]
58. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41. [PMID: 8861994]
59. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996; 276:1253-8. [PMID: 8849754]
60. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1172-7. [PMID: 8827972]
61. Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol. 2000;95:1881-7. [PMID: 10950030]
62. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33:306-9. [PMID: 11465182]
63. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103:1241-5. [PMID: 1397881]